Julian Symons
Direttore Tecnico/Scientifico/R&S presso ALIGOS THERAPEUTICS, INC.
Patrimonio netto: 322 344 $ in data 30/04/2024
Provenienza dei contatti di primo grado di Julian Symons
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 18 | |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA.
11
| Extinct | Pharmaceuticals: Major | 11 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Julian Symons tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
INTERMUNE INC | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal General Counsel | |
Plexxikon, Inc.
Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA. | Miscellaneous Commercial Services | Founder President | |
FLEXION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
TempestTx, Inc.
TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
Stanford University | College/University | Doctorate Degree Doctorate Degree | |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal | |
University of California, Berkeley | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Investment Managers | Private Equity Investor | |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Private Equity Investor | |
MacuLogix, Inc.
MacuLogix, Inc. Medical/Nursing ServicesHealth Services MacuLogix, Inc. engages in the early detection and tracking of retinal diseases. Its AdaptDx is the first practical measurement tool for dark adaptation which provides doctors with an easy-to-use functional test similar to routine perimetry testing for glaucoma. The company also provides macular degeneration services. The company was founded by John G. Edwards and Gregory R. Jackson in 2004 and is headquartered in Harrisburg, PA. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member General Counsel | |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Investment Managers | Private Equity Investor Corporate Officer/Principal Private Equity Investor | |
ALLAKOS INC. | Pharmaceuticals: Major | Director/Board Member Chairman | |
ADVERUM BIOTECHNOLOGIES, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Comptroller/Controller/Auditor | |
Inception Sciences, Inc.
Inception Sciences, Inc. Pharmaceuticals: MajorHealth Technology Inception Sciences, Inc. provides small molecule pharmaceutical incubator services. Its focus is on creating therapies with transformative potential to address diseases and disorders. The company creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded in 2011 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
CRISPR THERAPEUTICS AG | Biotechnology | Director/Board Member | |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Viewpoint Therapeutics, Inc.
Viewpoint Therapeutics, Inc. BiotechnologyHealth Technology Viewpoint Therapeutics, Inc. operates as a biotechnology company. It prevents and treats cataracts and presbyopia, and protein misfolding. The company was founded by Leah Makley in July of 2014 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member Director/Board Member | |
VAXCYTE, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Euro Ventures, Inc. | Founder | ||
Therachon SAS
Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Biotechnology | Chairman | |
GRITSTONE BIO, INC. | Biotechnology | Director/Board Member | |
Inception IBD, Inc.
Inception IBD, Inc. Miscellaneous Commercial ServicesCommercial Services Inception IBD, Inc. provides therapeutics services. It creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded by Eric Ogier-Denis, Yoram Bouhnik, Xavier Treton and Jacques Mizrahi in 2011 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Biotechnology | Chairman Director/Board Member | |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Versant Venture Capital VI (Canada) LP
Versant Venture Capital VI (Canada) LP Investment ManagersFinance Versant Venture Capital VI (Canada) LP operates as a pooled investment fund. The company is headquartered in San Francisco, CA. | Investment Managers | Director/Board Member | |
Jecure Therapeutics, Inc.
Jecure Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jecure Therapeutics, Inc. provides therapeutic services for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company was founded by Ariel Feldstein in 2015 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
CODA Biotherapeutics, Inc.
CODA Biotherapeutics, Inc. Medical SpecialtiesHealth Technology CODA Biotherapeutics, Inc. engages in the development of chemo genetic neuromodulation platform for the treatment of severe neurological disorders. The company was founded by Mitchell H. Finer, Allan Basbaum, Nicholas Boulis, Joseph Glorioso III and Kenneth P. Greenberg in 2014 and is headquartered in South San Francisco, CA. | Medical Specialties | Director/Board Member | |
Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member Chairman | |
PASSAGE BIO, INC. | Biotechnology | Director/Board Member | |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
Jengu Therapeutics, Inc.
Jengu Therapeutics, Inc. BiotechnologyHealth Technology Jengu Therapeutics, Inc. is a biotechnology company. The company is headquartered in San Diego, CA. | Biotechnology | Director/Board Member | |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Chairman | |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | Pharmaceuticals: Major | Director/Board Member | |
Okarios AG | Chief Operating Officer | ||
Santa Ana Bio, Inc.
Santa Ana Bio, Inc. BiotechnologyHealth Technology Santa Ana Bio, Inc. is a biotechnology company that specializes in precision immunology for autoimmune diseases. The company is based in Alameda, CA. The CEO of the company is Peter Emtage. | Biotechnology | Director/Board Member | |
TEMPEST THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
IO BIOTECH, INC. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
Abio-X Holdings, Inc. | Investor Relations Contact |
Statistiche
Distribuzione geografica
Stati Uniti | 38 |
Svizzera | 9 |
Danimarca | 5 |
Francia | 2 |
Settori
Health Technology | 33 |
Commercial Services | 7 |
Finance | 6 |
Consumer Services | 3 |
Health Services | 3 |
Posizioni
Director/Board Member | 179 |
Corporate Officer/Principal | 60 |
Independent Dir/Board Member | 50 |
Chairman | 22 |
Chief Tech/Sci/R&D Officer | 21 |
Contatti più connessi
Insiders | |
---|---|
Heath Lukatch | 43 |
Thomas Woiwode | 39 |
Jack Nielsen | 38 |
Carole Nüchterlein | 26 |
Jim Scopa | 26 |
Carol Brosgart | 25 |
Peter Moldt | 25 |
K. Hirth | 18 |
Bridget Martell | 17 |
Lawrence Blatt | 13 |
Kathleen Glaub | 13 |
Sunny Lee Ryan | 10 |
Lesley Calhoun | 9 |
Leonid Beigelman | 8 |
Rosanne Roth | 7 |
- Borsa valori
- Insiders
- Julian Symons
- Connessioni Società